) cut its earning per share guidance for 2005 by 6 cents to 12 cents, reflecting work delays and the negative impact of Hurricane Katrina. The technology services company sees lower-than-previosuly-guided revenue of $950 million, but expects its 2006 guidance will by largely unaffected by the hurricane.
Biogen Idec (BIIB
) is planning to cut its workforce by about 17% and will seek to divest several non-core assets. The biotech company's Executive Vice President of Research Michael Gilman is leaving. Thomas Weisel reportedly cut its opinion on the stock to underperform; Citigroup reportedly cut its opinion to hold.
Yellow Roadway (YELL
) said it expects third-quarter adjusted earnings per share of between $1.40 and $1.45 vs. previous guidance of $1.60 to $1.65. The company cited devastation caused by Hurricane Katrina, and implementation challenges for new processes at Roadway such as the associated learning curve.
Texas Instruments (TXN
) said it sees between 36 cents and 38 cents third-quarter earnings per share, including stock option expense, on revenue of between $3.48 billion and $3.62 billion. S&P raised its estimates and price target on the stock, but kept a hold investment recommendation.
) said it sees third-quarter revenue of between $9.8 billion and $10 billion, vs. its previous guidance of between $9.6 billion and $10.2 billion. The chip maker said its gross margin percentage is now expected to be 60%, plus or minus a point. S&P kept its hold opinion on the stock.
Martek Biosciences (MATK
) posted a breakeven third quarter, vs. 16 cents earnings per share, on 17% lower revenue. First Albany downgraded the stock to neutral from buy.
) posted 27 cents, vs. 30 cents, fourth-quarter earnings per share (before charges) despite a slight sales rise. S&P upgraded the stock to hold from sell.
Open Text (OTEX
) posted 10 cents, vs. 16 cents, fourth-quarter earnings per share (based on Generally Accepted Accounting Principles) despite a 4% rise in revenue. The software company sees first-quarter adjusted earnings per share of 4 cents to 15 cents on revenue of between $85 million and $95 million. It also expects to take the majority of a $25 million to $30 million restructuring charge in the first quarter. Jefferies upped its opinion on the stock to hold from underperform.
) posted 84 cents, vs. 51 cents, second quarter earnings per share on a 24% sales rise.
Progenics Pharmaceuticals (PGNX
) announced positive clinical findings regarding its investigational drug, PRO 140, which is a novel HIV entry inhibitor.
) posted 3.2% higher August same-store sales and raised its first-quarter earnings per share guidance to between 47 cents and 48 cents, excluding equity-based compensation expense.
Avid Technology (AVID
) signed a multimillion dollar broadcast deal with CBS to install its end-to-end digital newsroom environments at the network's New York City headquarters and London news bureau.
Biovail ( BVF
) said its New Drug Application for the once-daily formulation of tramadol hydrochloride received final approval from the Food and Drug Administration for the treatment of moderate to moderately severe chronic pain.
) posted 20 cents, vs. 16 cents, third-quarter earnings per share on an 11% revenue rise. The company sees 26 cents to 27 cents fourth quarter earnings per share and 86 cents to 87 cents fiscal year 2005 earnings per share.